Cover Image
市場調查報告書

高藥理活性原料藥 (HPAPI)的全球市場預測 2023年:合成HPAPI、生物科技HPAPI、moAB、疫苗、重組蛋白品質

High Potency APIs /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech, moAB, Vaccines, Recombinant Proteins), Manufacturer (Captive and Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecasts to 2023

出版商 MarketsandMarkets 商品編碼 544749
出版日期 內容資訊 英文 218 Pages
訂單完成後即時交付
價格
Back to Top
高藥理活性原料藥 (HPAPI)的全球市場預測 2023年:合成HPAPI、生物科技HPAPI、moAB、疫苗、重組蛋白品質 High Potency APIs /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech, moAB, Vaccines, Recombinant Proteins), Manufacturer (Captive and Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecasts to 2023
出版日期: 2018年04月18日 內容資訊: 英文 218 Pages
簡介

全球量藥理活性原料藥 (HPAPI) 市場規模,預計從2018年的177億2,000萬美元,到2023年達到268億4,000萬美元,期間為8.7%的年複合成長率。該市場的成長,由癌症治療藥、抗體-藥物複合體 (ADC)的需求增加,主要醫藥品企業對HPAPI的關注高漲,HPAPI製造技術的進步,及精密醫療受到高度的關注等要素所促進。同時,需要高額的投資,HPAPI的保險等級評級的差距,產品相關不確定性,二次污染高的風險等,預計抑制該市場的今後數年的成長。

本報告以全球量藥理活性原料藥 (HPAPI) 市場為研究主題,提供各種類、合成型、治療領域,及各地區的市場統計與分析,市場成長的影響因素分析,及主要企業簡介等資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 高藥理活性原料藥 (HPAPI) 市場概要
  • 高藥理活性原料藥 (HPAPI) 市場:各類型
  • 高藥理活性原料藥 (HPAPI) 市場:各合成型
  • 高藥理活性原料藥 (HPAPI) 市場:各治療領域
  • 高藥理活性原料藥 (HPAPI) 市場:各地區的概要

第5章 市場概要

  • 簡介
  • 市場動態
    • 促進要素
    • 抑制因素
    • 機會
    • 課題

第6章 高藥理活性原料藥 (HPAPI)的分類、概要

  • 簡介
  • 高藥理活性原料藥 (HPAPI)的分類:SAFEBRIDGE CONSULTANTS

第7章 高藥理活性原料藥 (HPAPI) 市場:各類型

  • 簡介
  • 創新的HPAPI
  • 非專利HPAPI

第8章 高藥理活性原料藥 (HPAPI) 市場:各合成型

  • 簡介
  • 合成HPAPI
  • 生物科技HPAPI

第9章 高藥理活性原料藥 (HPAPI) 市場:製造商的各類型

  • 簡介
  • 專屬製造商
  • 商家製造商
    • 各類型
    • 各合成型

第10章 高藥理活性原料藥 (HPAPI) 市場:各治療應用領域

  • 簡介
  • 癌症
  • 荷爾蒙失調
  • 青光眼
  • 其他治療應用

第11章 高藥理活性原料藥 (HPAPI) 市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞洲
  • 其他 (RoW)

第12章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢

第13章 企業簡介

  • PFIZER, INC.
  • NOVARTIS INTERNATIONAL AG
  • SANOFI
  • F. HOFFMANN-LA ROCHE LTD.
  • BRISTOL-MYERS SQUIBB
  • BOEHRINGER INGELHEIM
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • ELI LILLY AND COMPANY
  • MERCK & CO., INC.
  • ABBVIE INC.
  • MYLAN N.V.
  • BAYER

第14章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PH 4897

"The global HPAPIs market projected to grow at a CAGR of 8.7%"

The global HPAPIs market is expected to reach USD 26.84 billion by 2023 from USD 17.72 billion in 2018, at a CAGR 8.7%. The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine. On the other hand, the requirement of large investments, discrepancies in HPAPI banding systems, uncertainties associated with products, and the high risk of cross-contamination are expected to limit market growth in the coming years. The need for appropriate process designs and the constant evolution of industry standards and technologies are also expected to challenge market growth to a certain extent.

"The generic HPAPIs segment is expected to grow at the highest CAGR during the forecast period"

Based on type, the HPAPIs market is segmented into innovative and generic APIs. The generic HPAPIs segment is expected to register the highest growth rate during the forecast period. The impending patent cliff, increasing healthcare costs, and government initiatives to encourage the adoption of generics are the major factors driving the growth of this market segment.

"The captive manufacturers segment is expected to dominate the market in 2018"

On the basis of type of manufacturer, the HPAPIs market is segmented into captive HPAPI and merchant HPAPI manufacturers. In 2018, the captive HPAPI manufacturers segment is expected to account for the largest share of the market. The large share of this segment is attributed to the preference of innovative companies to maintain in-house manufacturing facilities for economic benefits.

"Asia to witness the highest growth during the forecast period"

In 2018, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to grow at the highest CAGR of 11.8% during the forecast period. Factors such as growth in geriatric population, high prevalence of chronic and lifestyle diseases, increase in disposable income, prevalence of lifestyle- and age-related diseases, government efforts to reform healthcare and encourage the adoption of generics, and growing market for merchant manufacturers in this region owing to the low labor and manufacturing costs are driving the growth of the HPAPIs market in Asia.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 31%; Tier 2 - 49%; Tier 3 - 20%
  • By Designation: C-level- 28%; D-level- 19%; Others- 53%
  • By Region: North America-31%; Europe-33%; Asia Pacific-19%; Rest of the World-17%

List of companies profiled in the report:

  • Pfizer (US)
  • Novartis International AG (Switzerland)
  • Sanofi (France)
  • F. Hoffmann-La Roche (Switzerland)
  • Bristol-Myers Squibb (US)
  • Boehringer Ingelheim (Germany)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Eli Lilly and Company (US)
  • Merck (US)
  • AbbVie (US)
  • Mylan (US)
  • Bayer (Germany)

Research Coverage:

The report provides an overview of the HPAPIs market. It aims at estimating the market size and future growth potential of this market across different segments such type, type of manufacturer, type of synthesis, therapeutic application, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall HPAPIs market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. STUDY SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. MARKET STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. SECONDARY DATA
    • 2.1.1. KEY DATA FROM SECONDARY SOURCES
  • 2.2. PRIMARY DATA
    • 2.2.1. KEY DATA FROM PRIMARIES
    • 2.2.2. INSIGHTS FROM INDUSTRY EXPERTS
  • 2.3. MARKET SIZE ESTIMATION
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS: MARKET OVERVIEW
  • 4.2. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018 VS. 2023(USD BILLION)
  • 4.3. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018 VS. 2023(USD BILLION)
  • 4.4. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC AREA (2018-2023)
  • 4.5. GEOGRAPHICAL SNAPSHOT OF THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing demand for oncology drugs
      • 5.2.1.2. Growing demand for antibody-drug conjugates
      • 5.2.1.3. Increasing focus of leading pharmaceutical companies on HPAPIs
      • 5.2.1.4. Advancements in HPAPI manufacturing technologies
      • 5.2.1.5. Growing focus on precision medicine
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Requirement of large investments
      • 5.2.2.2. Discrepancies in HPAPI banding systems
      • 5.2.2.3. Uncertainties associated with products
      • 5.2.2.4. High risk of cross-contamination
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Growing opportunities for CMOs and CDMOs
      • 5.2.3.2. Emerging markets
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Need for appropriate process designs
      • 5.2.4.2. Constant evolution of industry standards and technologies

6. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS CLASSIFICATION AND OVERVIEW

  • 6.1. INTRODUCTION
  • 6.2. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS CLASSIFICATION AS PER SAFEBRIDGE CONSULTANTS

7. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. INNOVATIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS
  • 7.3. GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS

8. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS

  • 8.1. INTRODUCTION
  • 8.2. SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS
    • 8.2.1. SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
      • 8.2.1.1. Innovative synthetic HPAPIs
      • 8.2.1.2. Generic synthetic HPAPIs
  • 8.3. BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS
    • 8.3.1. BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
      • 8.3.1.1. Innovative biotech HPAPIs
      • 8.3.1.2. Biosimilars
    • 8.3.2. BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT
      • 8.3.2.1. Monoclonal antibodies
      • 8.3.2.2. Vaccines
      • 8.3.2.3. Recombinant proteins

9. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER

  • 9.1. INTRODUCTION
  • 9.2. CAPTIVE HPAPI MANUFACTURERS
  • 9.3. MERCHANT HPAPI MANUFACTURERS
    • 9.3.1. MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE
      • 9.3.1.1. Innovative merchant HPAPI manufacturers
      • 9.3.1.2. Generic merchant HPAPI manufacturers
    • 9.3.2. MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS
      • 9.3.2.1. Synthetic HPAPIs
      • 9.3.2.2. Biotech HPAPIs

10. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION

  • 10.1. INTRODUCTION
  • 10.2. ONCOLOGY
  • 10.3. HORMONAL IMBALANCE
  • 10.4. GLAUCOMA
  • 10.5. OTHER THERAPEUTIC APPLICATIONS

11. HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. US
    • 11.2.2. CANADA
  • 11.3. EUROPE
    • 11.3.1. GERMANY
    • 11.3.2. FRANCE
    • 11.3.3. UK
    • 11.3.4. ITALY
    • 11.3.5. SPAIN
    • 11.3.6. REST OF EUROPE (ROE)
  • 11.4. ASIA
    • 11.4.1. JAPAN
    • 11.4.2. CHINA
    • 11.4.3. INDIA
    • 11.4.4. REST OF ASIA (ROA)
  • 11.5. REST OF THE WORLD (ROW)

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MARKET RANKING ANALYSIS
  • 12.3. COMPETITIVE SITUATION AND TRENDS
    • 12.3.1. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 12.3.2. MERGERS AND ACQUISITIONS
    • 12.3.3. EXPANSIONS

13. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 13.1. PFIZER
  • 13.2. NOVARTIS INTERNATIONAL AG
  • 13.3. SANOFI
  • 13.4. F. HOFFMANN-LA ROCHE
  • 13.5. BRISTOL-MYERS SQUIBB
  • 13.6. BOEHRINGER INGELHEIM
  • 13.7. TEVA PHARMACEUTICAL INDUSTRIES
  • 13.8. ELI LILLY AND COMPANY
  • 13.9. MERCK
  • 13.10. ABBVIE
  • 13.11. MYLAN
  • 13.12. BAYER

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.5. AVAILABLE CUSTOMIZATIONS
  • 14.6. RELATED REPORTS
  • 14.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: PIPELINE OF ONCOLOGY DRUGS (2018)
  • TABLE 2: THERAPEUTIC MONOCLONAL ANTIBODIES APPROVED BY THE FDA IN 2016
  • TABLE 3: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 4: INNOVATIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 5: NORTH AMERICA: INNOVATIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 6: EUROPE: INNOVATIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 7: ASIA: INNOVATIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 8: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 9: NORTH AMERICA: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 10: EUROPE: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 11: ASIA: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 12: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016- 2023 (USD MILLION)
  • TABLE 13: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016- 2023 (USD MILLION)
  • TABLE 14: NORTH AMERICA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 15: EUROPE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 16: ASIA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 17: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 18: INNOVATIVE SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016- 2023 (USD MILLION)
  • TABLE 19: NORTH AMERICA: INNOVATIVE SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 20: EUROPE: INNOVATIVE SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 21: ASIA: INNOVATIVE SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 22: GENERIC SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016- 2023 (USD MILLION)
  • TABLE 23: NORTH AMERICA: GENERIC SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 24: EUROPE: GENERIC SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 25: ASIA: GENERIC SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 26: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016- 2023 (USD MILLION)
  • TABLE 27: NORTH AMERICA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 28: EUROPE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 29: ASIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 30: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016- 2023 (USD MILLION)
  • TABLE 31: INNOVATIVE BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016- 2023 (USD MILLION)
  • TABLE 32: NORTH AMERICA: INNOVATIVE BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 33: EUROPE: INNOVATIVE BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 34: ASIA: INNOVATIVE BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 35: BIOSIMILARS MARKET, BY REGION, 2016- 2023 (USD MILLION)
  • TABLE 36: NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 37: EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 38: ASIA: BIOSIMILARS INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION)
  • TABLE 39: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016- 2023 (USD MILLION)
  • TABLE 40: MONOCLONAL ANTIBODIES MARKET, BY REGION, 2016- 2023 (USD MILLION)
  • TABLE 41: VACCINES MARKET, BY REGION, 2016- 2023 (USD MILLION)
  • TABLE 42: RECOMBINANT PROTEINS MARKET, BY REGION, 2016- 2023 (USD MILLION)
  • TABLE 43: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 44: CAPTIVE HPAPI MANUFACTURERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 45: NORTH AMERICA: CAPTIVE HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 46: EUROPE: CAPTIVE HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 47: ASIA: CAPTIVE HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 48: MERCHANT HPAPI MANUFACTURERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 49: NORTH AMERICA: MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 50: EUROPE: MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 51: ASIA: MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 52: GLOBAL MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023, (USD MILLION)
  • TABLE 53: INNOVATIVE MERCHANT HPAPI MANUFACTURERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 54: NORTH AMERICA: INNOVATIVE MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 55: EUROPE: INNOVATIVE MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 56: ASIA: INNOVATIVE MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 57: GENERIC MERCHANT HPAPI MANUFACTURERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 58: NORTH AMERICA: GENERIC MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 59: EUROPE: GENERIC MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 60: ASIA: GENERIC MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 61: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023, (USD MILLION)
  • TABLE 62: MERCHANT SYNTHETIC HPAPI MANUFACTURERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 63: NORTH AMERICA: MERCHANT SYNTHETIC HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 64: EUROPE: MERCHANT SYNTHETIC HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 65: ASIA: MERCHANT SYNTHETIC HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 66: MERCHANT BIOTECH HPAPI MANUFACTURERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 67: NORTH AMERICA: MERCHANT BIOTECH HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 68: EUROPE: MERCHANT BIOTECH HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 69: ASIA: MERCHANT BIOTECH HPAPI MANUFACTURERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 70: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 71: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 72: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 73: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 74: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 75: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONAL IMBALANCE, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 76: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 77: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 78: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 79: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GLAUCOMA, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 80: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GLAUCOMA, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 81: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GLAUCOMA, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 82: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GLAUCOMA, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 83: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 84: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 85: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 86: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 87: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 88: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 89: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 90: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 91: NORTH AMERICA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 92: NORTH AMERICA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 93: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 94: NORTH AMERICA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 95: NORTH AMERICA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 96: NORTH AMERICA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 97: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 98: US: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 99: US: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 100: US: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 101: US: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 102: US: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 103: US: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 104: US: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION
  • TABLE 105: US: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 106: US: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 107: CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 108: CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 109: CANADA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 110: CANADA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 111: CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 112: CANADA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 113: CANADA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 114: CANADA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 115: CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 116: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 117: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 118: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 119: EUROPE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 120: EUROPE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 121: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 122: EUROPE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 123: EUROPE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 124: EUROPE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 125: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 126: GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 127: GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 128: GERMANY: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 129: GERMANY: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 130: GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 131: GERMANY: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 132: GERMANY: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 133: GERMANY: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 134: GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 135: FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 136: FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 137: FRANCE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 138: FRANCE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 139: FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 140: FRANCE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 141: FRANCE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 142: FRANCE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 143: FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 144: UK: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 145: UK: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 146: UK: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 147: UK: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 148: UK: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 149: UK: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 150: UK: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 151: UK: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 152: UK: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 153: ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 154: ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 155: ITALY: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 156: ITALY: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 157: ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 158: ITALY: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 159: ITALY: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 160: ITALY: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 161: ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 162: SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 163: SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 164: SPAIN: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 165: SPAIN: MERCHANT MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 166: SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 167: SPAIN: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 168: SPAIN: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 169: SPAIN: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 170: SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 171: ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 172: ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 173: ROE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 174: ROE: MERCHANT MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 175: ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 176: ROE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 177: ROE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 178: ROE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 179: ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 180: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 181: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 182: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 183: ASIA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 184: ASIA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 185: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 186: ASIA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 187: ASIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 188: ASIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 189: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 190: JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 191: JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 192: JAPAN: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 193: JAPAN: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 194: JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 195: JAPAN: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 196: JAPAN: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 197: JAPAN: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 198: JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 199: CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 200: CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 201: CHINA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 202: CHINA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 203: CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 204: CHINA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 205: CHINA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 206: CHINA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 207: CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION) 163  
  • TABLE 208: INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 209: INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 210: INDIA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 211: INDIA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 212: INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 213: INDIA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 214: INDIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 215: INDIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 216: INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 217: ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 218: ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 219: ROA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 220: ROA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 221: ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 222: ROA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 223: ROA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 224: ROA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 225: ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 226: ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 227: ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016-2023 (USD MILLION)
  • TABLE 228: ROW: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 229: ROW: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 230: ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016-2023 (USD MILLION)
  • TABLE 231: ROW: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 232: ROW: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016-2023 (USD MILLION) 175  
  • TABLE 233: ROW: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 234: ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 235: MARKET RANKING ANALYSIS, BY KEY PLAYER, 2017
  • TABLE 236: AGREEMENTS, COLLABORATIONS, PARTNERSHIPS, AND ALLIANCES (2015-2018)
  • TABLE 237: MERGERS AND ACQUISITIONS (2015-2018)
  • TABLE 238: EXPANSIONS (2015-2018)
  • TABLE 239: EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF CHF TO USD)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018 VS. 2023
  • FIGURE 7: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018 VS. 2023
  • FIGURE 8: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018 VS. 2023
  • FIGURE 9: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018 VS. 2023
  • FIGURE 10: GEOGRAPHIC SNAPSHOT OF THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET (2018-2023)
  • FIGURE 11: INCREASING DEMAND FOR ONCOLOGY DRUGS & ANTIBODY-DRUG CONJUGATES-MAJOR FACTOR DRIVING MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 12: INNOVATIVE HPAPIS WILL CONTINUE TO DOMINATE THE GLOBAL MARKET IN 2023
  • FIGURE 13: SYNTHETIC HPAPIS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018
  • FIGURE 14: ONCOLOGY SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 15: CHINA & INDIA TO REGISTER HIGH GROWTH RATES DURING 2018-2023
  • FIGURE 16: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
  • FIGURE 18: INNOVATIVE HPAPIS SEGMENT TO DOMINATE THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN 2018
  • FIGURE 19: SYNTHETIC SEGMENT TO DOMINATE THE MARKET IN 2018
  • FIGURE 20: CAPTIVE HPAPI MANUFACTURERS SEGMENT IS EXPECTED TO ACCOUNT FOR LARGEST SHARE OF THE MARKET IN 2018
  • FIGURE 21: NORTH AMERICA TO DOMINATE THE CAPTIVE HPAPI MANUFACTURERS MARKET IN 2018
  • FIGURE 22: ONCOLOGY SEGMENT TO DOMINATE THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION (2018)
  • FIGURE 23: ASIA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2018-2023)
  • FIGURE 24: NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT (2018)
  • FIGURE 25: EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
  • FIGURE 26: ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
  • FIGURE 27: REST OF THE WORLD: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
  • FIGURE 28: KEY DEVELOPMENTS IN THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2015-2018
  • FIGURE 29: MARKET EVOLUTION FRAMEWORK- AGREEMENTS, COLLABORATIONS, PARTNERSHIPS, AND ALLIANCES FUELED MARKET GROWTH
  • FIGURE 30: BATTLE FOR MARKET SHARE: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS (2015-2018)
  • FIGURE 31: PFIZER: COMPANY SNAPSHOT (2016)
  • FIGURE 32: NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2016)
  • FIGURE 33: SANOFI: COMPANY SNAPSHOT (2017)
  • FIGURE 34: F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2017)
  • FIGURE 35: BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2016)
  • FIGURE 36: BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2016)
  • FIGURE 37: TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT (2017)
  • FIGURE 38: ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2016)
  • FIGURE 39: MERCK: COMPANY SNAPSHOT (2016)
  • FIGURE 40: ABBVIE: COMPANY SNAPSHOT (2017)
  • FIGURE 41: MYLAN: COMPANY SNAPSHOT (2017)
  • FIGURE 42: BAYER: COMPANY SNAPSHOT (2017)
Back to Top